Want to see HK:6185 full AI Analyst Report?
CanSino Biologics, Inc. Class H (6185) Ratios
CanSino Biologics, Inc. Class H Ratios
HK:6185's free cash flow for Q3 2026 was $49.81M. For the 2026 fiscal year, HK:6185's free cash flow was decreased by $-36.81M and operating cash flow was $86.62M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.55 | 2.42 | 2.00 | 2.63 | 3.23 |
| Quick Ratio | 3.23 | 2.26 | 1.86 | 2.40 | 2.93 |
| Cash Ratio | 1.14 | 0.88 | 0.79 | 1.15 | 1.90 |
| Solvency Ratio | 0.10 | -0.05 | -0.30 | -0.17 | 0.60 |
| Operating Cash Flow Ratio | 0.03 | -0.10 | -0.35 | -0.64 | 0.70 |
| Short-Term Operating Cash Flow Coverage | 0.10 | -0.19 | -0.66 | -1.20 | 1.86 |
| Net Current Asset Value | $ 1.79B | $ 1.23B | $ 1.15B | $ 3.51B | $ 5.96B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.25 | 0.29 | 0.24 | 0.12 |
| Debt-to-Equity Ratio | 0.26 | 0.41 | 0.51 | 0.40 | 0.17 |
| Debt-to-Capital Ratio | 0.21 | 0.29 | 0.34 | 0.29 | 0.15 |
| Long-Term Debt-to-Capital Ratio | 0.16 | 0.18 | 0.17 | 0.12 | 0.00 |
| Financial Leverage Ratio | 1.45 | 1.62 | 1.77 | 1.70 | 1.49 |
| Debt Service Coverage Ratio | 0.18 | -0.14 | -1.12 | -0.68 | 1.65 |
| Interest Coverage Ratio | -2.03 | -6.26 | -31.73 | -33.11 | 95.05 |
| Debt to Market Cap | 0.16 | 0.27 | 0.49 | 0.17 | 0.03 |
| Interest Debt Per Share | 5.31 | 8.37 | 11.20 | 11.10 | 5.64 |
| Net Debt to EBITDA | 0.87 | -3.39 | -0.40 | 0.53 | -2.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 66.07% | 71.12% | -253.78% | -18.10% | 69.85% |
| EBIT Margin | -10.96% | -44.33% | -554.70% | -145.39% | 41.49% |
| EBITDA Margin | 5.91% | -15.93% | -476.76% | -127.91% | 43.01% |
| Operating Profit Margin | -10.96% | -44.33% | -589.60% | -132.75% | 45.14% |
| Pretax Profit Margin | 2.05% | -45.04% | -573.29% | -114.84% | 45.04% |
| Net Profit Margin | 2.63% | -44.77% | -429.55% | -88.21% | 44.52% |
| Continuous Operations Profit Margin | 2.63% | -45.33% | -569.97% | -93.57% | 44.35% |
| Net Income Per EBT | 128.22% | 99.39% | 74.93% | 76.81% | 98.84% |
| EBT Per EBIT | -18.72% | 101.59% | 97.23% | 86.50% | 99.79% |
| Return on Assets (ROA) | 0.38% | -4.76% | -15.91% | -7.93% | 16.12% |
| Return on Equity (ROE) | 0.55% | -7.72% | -28.11% | -13.48% | 23.94% |
| Return on Capital Employed (ROCE) | -1.85% | -6.07% | -30.25% | -16.05% | 21.57% |
| Return on Invested Capital (ROIC) | -1.76% | -5.29% | -24.72% | -10.99% | 18.90% |
| Return on Tangible Assets | 0.39% | -4.93% | -16.27% | -8.11% | 16.40% |
| Earnings Yield | 0.34% | -5.17% | -29.34% | -6.25% | 5.27% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.30 | 1.07 | 0.50 | 1.21 | 27.23 |
| Payables Turnover | 6.94 | 3.91 | 11.75 | 4.81 | 1.54 |
| Inventory Turnover | 1.03 | 0.87 | 3.46 | 1.80 | 1.48 |
| Fixed Asset Turnover | 0.38 | 0.32 | 0.11 | 0.33 | 1.94 |
| Asset Turnover | 0.14 | 0.11 | 0.04 | 0.09 | 0.36 |
| Working Capital Turnover Ratio | 0.39 | 0.33 | 0.09 | 0.18 | 0.75 |
| Cash Conversion Cycle | 580.69 | 667.73 | 811.21 | 430.15 | 22.71 |
| Days of Sales Outstanding | 280.49 | 342.13 | 736.82 | 302.85 | 13.41 |
| Days of Inventory Outstanding | 352.80 | 418.89 | 105.46 | 203.17 | 246.51 |
| Days of Payables Outstanding | 52.60 | 93.29 | 31.08 | 75.87 | 237.21 |
| Operating Cycle | 633.29 | 761.02 | 842.28 | 506.02 | 259.92 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.13 | -0.68 | -3.71 | -7.64 | 8.14 |
| Free Cash Flow Per Share | -0.60 | -2.53 | -6.19 | -11.99 | 3.28 |
| Dividend Paid and CapEx Coverage Ratio | 0.18 | -0.32 | -1.49 | -1.49 | 1.66 |
| Capital Expenditure Coverage Ratio | 0.18 | -0.37 | -1.50 | -1.76 | 1.67 |
| Operating Cash Flow Coverage Ratio | 0.03 | -0.08 | -0.34 | -0.70 | 1.47 |
| Operating Cash Flow to Sales Ratio | 0.03 | -0.20 | -2.65 | -1.83 | 0.47 |
| Free Cash Flow Yield | -1.92% | -8.55% | -30.21% | -20.35% | 2.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 285.14 | -19.34 | -3.41 | -16.01 | 18.97 |
| Price-to-Sales (P/S) Ratio | 7.70 | 8.66 | 14.64 | 14.12 | 8.45 |
| Price-to-Book (P/B) Ratio | 1.60 | 1.49 | 0.96 | 2.16 | 4.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -52.00 | -11.70 | -3.31 | -4.91 | 44.75 |
| Price-to-Operating Cash Flow Ratio | 244.64 | -43.41 | -5.52 | -7.71 | 18.03 |
| Price-to-Earnings Growth (PEG) Ratio | -2.66 | 0.26 | -0.05 | 0.11 | -0.03 |
| Enterprise Value Multiple | 131.20 | -57.72 | -3.47 | -10.51 | 17.43 |
| Enterprise Value | 8.00B | 7.78B | 5.71B | 13.87B | 32.23B |
| EV to EBITDA | 131.20 | -57.72 | -3.47 | -10.51 | 17.43 |
| EV to Sales | 7.75 | 9.20 | 16.53 | 13.45 | 7.50 |
| EV to Free Cash Flow | -52.35 | -12.42 | -3.74 | -4.68 | 39.72 |
| EV to Operating Cash Flow | 246.27 | -46.11 | -6.23 | -7.35 | 16.00 |
| Tangible Book Value Per Share | 19.37 | 18.73 | 20.59 | 28.28 | 33.74 |
| Shareholders’ Equity Per Share | 19.56 | 19.83 | 21.37 | 27.32 | 32.31 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.28 | -0.01 | 0.01 | 0.19 | 0.02 |
| Revenue Per Share | 4.07 | 3.42 | 1.40 | 4.17 | 17.38 |
| Net Income Per Share | 0.11 | -1.53 | -6.01 | -3.68 | 7.74 |
| Tax Burden | 1.28 | 0.99 | 0.75 | 0.77 | 0.99 |
| Interest Burden | -0.19 | 1.02 | 1.03 | 0.79 | 1.09 |
| Research & Development to Revenue | 0.22 | 0.49 | 1.85 | 0.75 | 0.20 |
| SG&A to Revenue | 0.57 | 0.67 | 0.85 | 0.27 | 0.05 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.03 | 0.01 | 0.00 |
| Income Quality | 1.20 | 0.44 | 0.62 | 1.59 | 1.06 |
Currency in CNY